Clinical Trials Logo

Pyoderma Gangrenosum clinical trials

View clinical trials related to Pyoderma Gangrenosum.

Filter by:

NCT ID: NCT01965613 Completed - Clinical trials for Pyoderma Gangrenosum

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Start date: January 31, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

NCT ID: NCT01952275 Recruiting - Clinical trials for Pyoderma Gangrenosum

Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases

NEUTROGENE
Start date: January 2014
Phase: N/A
Study type: Observational

This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin Diseases. After collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a discovery cohort formed based on the certainty of diagnosis. The DNA of patients in the discovery cohort is analyzed by whole exome sequencing which identifies all protein-coding genetic variants. Subsequently, statistical burden tests are going to identify enrichment of rare coding genetic variants in patients affected by Neutrophil-Mediated Inflammatory Skin Diseases. The ultimate goal is to reveal the responsible gene(s) that may then be targets for clinical intervention.

NCT ID: NCT01882504 Completed - Clinical trials for Pyoderma Gangrenosum

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.

NCT ID: NCT01302795 Completed - Clinical trials for Pyoderma Gangrenosum

Canakinumab for Pyoderma Gangrenosum

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.

NCT ID: NCT00791557 Completed - Ulcerative Colitis Clinical Trials

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

Start date: October 2008
Phase: N/A
Study type: Interventional

Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.

NCT ID: NCT00730717 Withdrawn - Clinical trials for Pyoderma Gangrenosum

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of Humira in the treatment of pyoderma gangrenosum.

NCT ID: NCT00690846 Withdrawn - Clinical trials for Pyoderma Gangrenosum

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if Humira (adalimumab) is effective and safe in the treatment of pyoderma gangrenosum.